However, clinical trials of mTOR inhibitors demonstrated regression of tumours in the brain and kidney and stabilisation of lung function in those patients with lymphangioleiomyomatosis (LAM) [144–146]. Here, MTOR is linked to lymphangioleiomyomatosis.